专利号:US-3972945-A 优先权日:1974-12-23 标 题:Process for the selective synthesis of salicylaldehydes 发明人:ALBRIGHT CHARLES F 权利人:GARRETT CORP 摘要:The classical Reimer-Tiemann reaction for the synthesis of phenolic aldehydes has been modified from an aqueous to a non-aqueous system to provide an improved route for the formation of salicylaldehydes and, preferably, 3-substituted salicylaldehydes, e.g. 3-fluorosalicylaldehyde. Heretofore, compounds such as 3-substituted salicylaldehydes have proven to be extremely difficult to prepare in other than small laboratory quantities from the corresponding ortho-substituted phenol, since, in the final salicylaldehyde, each position ortho to the hydroxyl group contains substitution. In particular, with respect to 3-fluorosalicylaldehyde, one of the positions is occupied by the strongly electronegative fluorine atom so that the principal reaction product in the aqueous Reimer-Tiemann reaction has always been the para-isomer (3-fluoro-4-hydroxy-benzaldehyde), only negligible quantities of the desired ortho-isomer being obtained. In the process of the present invention, o-fluorophenol is caused to react with sodium hydroxide and chloroform in a hydrocarbon diluent (preferably benzene), maintaining the reaction under essentially anhydrous conditions by taking up the water of reaction with excess sodium hydroxide. It is necessary that an aprotic solvent, such as N,N-dimethylformamide, be employed as a catalyst. The use of boron oxide, while not absolutely necessary to the reaction, has been found to be advantageous in that the reaction proceeds more smoothly if the phenoxyboroxine is formed initially. The boron oxide also acts as a dehydrating agent and aids in removing the water of reaction. The preferential reaction product is the desired 3-fluorosalicylaldehyde, no paraisomer having been found. After hydrolysis and neutralization, the 3-fluorosalicylaldehyde can be recovered by azeotropic distillation along with a substantial quantity of unreacted o-fluorophenol which can be purified for recycle in subsequent preparations.
专利号:US-7339065-B2 优先权日:2003-07-21 标题 :Design and synthesis of optimized ligands for PPAR 发明人:AVERY MITCHELL A; PERSHADSINGH HARRIHAR A 权利人:BETHESDA PHARMACEUTICALS INC; UNIV MISSISSIPPI 摘要:This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.
专利号:US-11976052-B2 优先权日:2019-01-11 标题:Leukotriene synthesis inhibitors 发明人:BURGOYNE DAVID L; DEBRUIN ERIN; FONAREV JULIA; YEE JAMES GEE KEN; LANGLANDS JOHN MICHAEL 权利人:NAEGIS PHARMACEUTICALS INC 摘要:Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.
专利号:US-2007099969-A1 优先权日:2003-07-21 标题 :Design and synthesis of optimized ligands for ppar
专利号:US-2022274997-A1 优先权日:2019-04-29 标题:Pim kinase inhibitor compositions and uses thereof 发明人:BURK MARK J; CHEN BRANDON 权利人:SNAP BIO INC 摘要:This disclosure relates to compounds and compositions useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.
专利号:US-2009137577-A1 优先权日:2007-06-29 标 题 :Heterocyclic compounds 发明人:DUPLANTIER ALLEN J; EFREMOV IVAN; ZHANG LEI; MAKLAD NOHA S; O'SULLIVAN THERESA 权利人:PFIZER 摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n n n n n n n n n n as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.